Dartmouth Health Continuing Education for Professionals Home, Medicine Grand Rounds - Open Questions in Colorectal Cancer Screening, 11/12/2021 8:00:00 AM - 11/12/2024 9:00:00 AM, Participants in Medicine Grand Rounds will be able to identify the most current treatment guidelines, innovations, and standards of practice, and apply them to improve the care of individual patients, promote health and wellness in the population, and achieve clinical quality and safety goals. These educational activities are grounded in principles of health equity, evidence based medicine, inter-professional teamwork, patient-centered care, and respect for human dignity.
Presenter
Douglas J. Robertson, MD, MPH
Chief, Gastroenterology
White River Junction VA Medical Center
Professor of Medicine
Geisel School of Medicine at Dartmouth and The Dartmouth Institute
About our Presenter
Dr. Douglas Robertson earned his MD and completed his residency in Internal Medicine at the University of Connecticut. He completed his Gastroenterology fellowship at the University of North Carolina (UNC) at Chapel Hill, and during that time also earned and MPH in Epidemiology from the UNC School of Public Health. His research interests include the epidemiology of colorectal cancer (CRC) and the utility of screening and surveillance for this disease.
Learning Outcome(s)
Participants will be able to provide specific guidance to patients on absolute and relative risk for colorectal cancer and the best evidence supporting effective and adherent colorectal cancer screening.
Disclosure
The following activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content for this activity have reported the following financial relationship(s)* with ineligible company(ies)**. All of the relevant financial relationships listed for these individuals have been mitigated.
* Richard I. Rothstein, MD ~ has research support from Fractyl and is on the Scientific Advisory Board for Allurion.
* Douglas J. Robertson, MD, MPH ~ is a consultant/advisor for Amadix and Freenome.
Other planning committee member(s), speaker(s), activity director(s), author(s) or anyone in a position to control the content for this activity report NO financial relationship(s)* with any ineligible company(ies)**.
* A “financial relationship" includes employee, researcher (named as the PI), consultant, advisor, speaker, independent contractor (including contracted research), royalties or patent beneficiary, executive role, and/or an ownership interest (not including stocks owned in a managed portfolio).
** An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Bibliographic Material
See presentation for bibliographic sources to allow for further study.
Presenter
Douglas J. Robertson, MD, MPH
Chief, Gastroenterology
White River Junction VA Medical Center
Professor of Medicine
Geisel School of Medicine at Dartmouth and The Dartmouth Institute
About our Presenter
Dr. Douglas Robertson earned his MD and completed his residency in Internal Medicine at the University of Connecticut. He completed his Gastroenterology fellowship at the University of North Carolina (UNC) at Chapel Hill, and during that time also earned and MPH in Epidemiology from the UNC School of Public Health. His research interests include the epidemiology of colorectal cancer (CRC) and the utility of screening and surveillance for this disease.
Learning Outcome(s)
Participants will be able to provide specific guidance to patients on absolute and relative risk for colorectal cancer and the best evidence supporting effective and adherent colorectal cancer screening.
Disclosure
The following activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content for this activity have reported the following financial relationship(s)* with ineligible company(ies)**. All of the relevant financial relationships listed for these individuals have been mitigated.
* Richard I. Rothstein, MD ~ has research support from Fractyl and is on the Scientific Advisory Board for Allurion.
* Douglas J. Robertson, MD, MPH ~ is a consultant/advisor for Amadix and Freenome.
Other planning committee member(s), speaker(s), activity director(s), author(s) or anyone in a position to control the content for this activity report NO financial relationship(s)* with any ineligible company(ies)**.
* A “financial relationship" includes employee, researcher (named as the PI), consultant, advisor, speaker, independent contractor (including contracted research), royalties or patent beneficiary, executive role, and/or an ownership interest (not including stocks owned in a managed portfolio).
** An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Bibliographic Material
See presentation for bibliographic sources to allow for further study.
